CSPC Pharmaceutical Group: AstraZeneca licence income and finished-drug growth lifted 9M revenue 27% and profit 101.5%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

9M revenue grew 27.0% and reported profit attributable to shareholders rose 101.5%, supported by finished-drug sales and AstraZeneca licence income. Bulk products and functional food declined amid price, competition and procurement pressures.

Original document: CSPC Pharmaceutical Group Limited [1093] Earnings Release — Nov. 18 2026

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.